APA (7th ed.) Citation

3rd, B. G., J, C., J, S., M, O., P, A., A, M., . . . EH, G. (2023). Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: Time for a reappraisal. Pediatric nephrology (Berlin, Germany), 38(1), 145. https://doi.org/10.1007/s00467-022-05549-7

Chicago Style (17th ed.) Citation

3rd, Burke GW, et al. "Benefit of B7-1 Staining and Abatacept for Treatment-resistant Post-transplant Focal Segmental Glomerulosclerosis in a Predominantly Pediatric Cohort: Time for a Reappraisal." Pediatric Nephrology (Berlin, Germany) 38, no. 1 (2023): 145. https://doi.org/10.1007/s00467-022-05549-7.

MLA (9th ed.) Citation

3rd, Burke GW, et al. "Benefit of B7-1 Staining and Abatacept for Treatment-resistant Post-transplant Focal Segmental Glomerulosclerosis in a Predominantly Pediatric Cohort: Time for a Reappraisal." Pediatric Nephrology (Berlin, Germany), vol. 38, no. 1, 2023, p. 145, https://doi.org/10.1007/s00467-022-05549-7.